FIELD: medicine, pharmaceutics.
SUBSTANCE: there are offered: a pharmaceutical composition containing a mitotic disruptor/a polo-like kinase (Plk) biochemical path inhibitor, particularly ON01910, ON01910-Na or Plkl-targeted siRNA, and a chemotherapeutic agent representing a nucleotide analogue in an effective amount, as well as an acceptable carrier to be used as a drug to prevent developing resistance to the chemotherapeutic agent representing the nucleotide analogue in an individual suffering cancer, or to be used as a drug for treating cancer resistant to the chemotherapeutic agent representing the nucleotide analogue in a patient in need thereof, and the same intended use of the mitotic disruptor/the polo-like kinase (Plk) biochemical path inhibitor, particularly ON01910, ON01910-Na or Plkl-targeted siRNA, and the chemotherapeutic agent representing the nucleotide analogue.
EFFECT: what is shown is a synergic effect of the declared combination and negotiation or prevention of developing resistance to the chemotherapeutic agent.
15 cl, 3 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING CANCER CARRYING EGFR MUTATIONS | 2007 |
|
RU2492864C2 |
| METHOD OF INDUCING APOPTOSIS OF MALIGNANT TUMOUR CELLS OF COLORECTAL CANCER AND MEANS FOR ITS REALISATION | 2013 |
|
RU2551238C9 |
| COMBINED CHEMOTHERAPY | 2001 |
|
RU2284818C2 |
| METHOD FOR REDUCING MULTI-DRUG RESISTANCE WITH USING INOSITOL TRIPYROPHOSPHATE | 2010 |
|
RU2563127C2 |
| COMPOSITION FOR INHIBITING GROWTH AND STIMULATION OF APOPTOSIS OF COLORECTAL CANCER CELLS | 2016 |
|
RU2644675C1 |
| COMBINED CHEMOTHERAPY | 2010 |
|
RU2587013C2 |
| COMBINED CHEMOTHERAPY | 2006 |
|
RU2429838C2 |
| METHODS FOR TREATMENT OF METASTATIC CANCER TYPES, USING AXL TRAP RECEPTORS | 2018 |
|
RU2785866C2 |
| IMMUNE RESPONSE PRESERVATION DURING CHEMOTHERAPEUTICAL SHEMES | 2017 |
|
RU2779478C2 |
| TREATMENT OF PANCREATIC CANCER | 2018 |
|
RU2792690C2 |
